Summary and Recommendation
We reiterate our positive outlook on Bacterin International Holding, Inc. (NYSE MKT: BONE) shares given the company's recent hiring of new CEO Dan Goldberger and the satisfactory resolution of recent overhangs associated with the FDA and OIG inquiries.
Bacterin develops bone graft materials and biologic allografts for transplantation. The Company also develops bioactive coating technologies for implantable devices
Over the past 12 months shares of Bacterin International Holdings (NYSE MKT: BONE) have been under intense pressure having fallen from its highs of $1.82 to now below $0.60. The company has been wrought with a series of negative headlines from missing guidance, warning letters from the FDA, subpoena from the OIG and the departure of their...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: